Skip to content

Microbiology of Severe Acute Tonsillitis, Peritonsillar Cellulitis, and Infectious Mononucleosis

Mikrobiologi Ved svær Akut Tonsillit, peritonsillær Phlegmone og infektiøs Mononukleose

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02715037
Enrollment
350
Registered
2016-03-22
Start date
2016-06-30
Completion date
2021-12-31
Last updated
2016-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Tonsillitis, Infectious Mononucleosis, Peritonsillar Cellulitis

Keywords

fusobacterium necrophorum, acute tonsillitis, peritonsillar cellulitis, infectious mononucleosis, microbiology, antibody development

Brief summary

Prospective, observational study of the microbiology of patients referred to a tertiary care center with severe acute tonsillitis, peritonsillar cellulitis, or infectious mononucleosis.

Detailed description

Patients referred to tertiary care centers with acute throat infections are most often treated with antibiotics. However, very little is know concerning the prevalent pathogens in patients with acute throat infections without abscess formation. Evidence suggests that Fusobacterium necrophorum plays an important role in complications of acute tonsillitis (e.g. peritonsillar abscess), but also uncomplicated acute tonsillitis. This study aims to explore the throat microbiology of patients with severe acute tonsillitis, peritonsillar cellulitis, or infectious mononucleosis with a special attention to a possible role of Fusobacterium necrophorum.

Interventions

OTHERThroat swabbing

Sponsors

Statens Serum Institut
CollaboratorOTHER
Tejs Ehlers Klug
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

1. Patients referred to our tertiary care center with acute tonsillitis with or without signs of peritonsillar cellulitis and with or without infectious mononucleosis. 2. Center Score 3 or 4.

Exclusion criteria

1. Abscess formation. 2. Previous tonsillectomy.

Design outcomes

Primary

MeasureTime frame
Prevalence of Fusobacterium necrophorum in throat swab culturesAt acute consultation (day 0)

Secondary

MeasureTime frameDescription
Number of participants with recurrent throat infections (questionnaire)Six months after acute consultation
Number of participants without eradication of throat pathogens (throat cultures)14-28 days after acute consultationThroat pathogens: Fusobacterium necrophorum, Beta-hemolytical streptococci, A. hemolyticum
Number of participants with complications of severe acute tonsillitis, peritonsillar cellulitis, and infectious mononucleosis14-28 days after acute consultationComplications: admission, abscess Development, change of antibiotic treatment
Prevalence of anti-Fusobacterium necrophorum antibody Development (two-fold or higher increase in antibody level) (blood samples)In acute and convalescent sera (day 0 and 14-28)Comparison of the prevalence of antibody Development (two-fold or higher increase in antibody level) between patients with recovery of Fusobacterium necrophorum in throat swabs versus patients without recovery of Fusobacterium necrophorum in throat swabs

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026